Treatment of neuromyelitis optica: Review and recommendations

Dorlan J. Kimbrough; Kazuo Fujihara; Anu Jacob; Marco A. Lana-Peixoto; Maria Isabel Leite; Michael Levy; Romain Marignier; Ichiro Nakashima; Jacqueline Palace; Jrme De Seze; Olaf Stuve; Silvia N. Tenembaum; Anthony Traboulsee; Emmanuelle Waubant; Brian G. Weinshenker; Dean M. Wingerchuk

doi:10.1016/j.msard.2012.06.002

Treatment of neuromyelitis optica: Review and recommendations

Dorlan J. Kimbrough, Kazuo Fujihara, Anu Jacob, Marco A. Lana-Peixoto, Maria Isabel Leite, Michael Levy, Romain Marignier, Ichiro Nakashima, Jacqueline Palace, Jrme De Seze, Olaf Stuve, Silvia N. Tenembaum, Anthony Traboulsee, Emmanuelle Waubant, Brian G. Weinshenker, Dean M. Wingerchuk

Research output: Contribution to journal › Review article › peer-review

169 Scopus citations

Abstract

Neuromyelitis optica (NMO) is an autoimmune demyelinating disease preferentially targeting the optic nerves and spinal cord. Once regarded as a variant of multiple sclerosis (MS), NMO is now recognized to be a different disease with unique pathology and immunopathogenesis that does not respond to traditional MS immunomodulators such as interferons. Preventive therapy in NMO has focused on a range of immunosuppressive medications, none of which have been validated in a rigorous randomized trial. However, multiple retrospective and a few recent prospective studies have provided evidence for the use of six medications for the prevention of NMO exacerbations: azathioprine, rituximab, mycophenolate mofetil, prednisone, methotrexate and mitoxantrone. This review provides a comprehensive analysis of each of these medications in NMO and concludes with a set of recommended consensus practices.

Original language	English (US)
Pages (from-to)	180-187
Number of pages	8
Journal	Multiple Sclerosis and Related Disorders
Volume	1
Issue number	4
DOIs	https://doi.org/10.1016/j.msard.2012.06.002
State	Published - Oct 2012

Keywords

Aquaporin 4
Immunosuppression
NMO treatment
Neuromyelitis optica
Optic neuritis
Transverse myelitis

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1016/j.msard.2012.06.002

Cite this

Kimbrough, D. J., Fujihara, K., Jacob, A., Lana-Peixoto, M. A., Isabel Leite, M., Levy, M., Marignier, R., Nakashima, I., Palace, J., De Seze, J., Stuve, O., Tenembaum, S. N., Traboulsee, A., Waubant, E., Weinshenker, B. G., & Wingerchuk, D. M. (2012). Treatment of neuromyelitis optica: Review and recommendations. Multiple Sclerosis and Related Disorders, 1(4), 180-187. https://doi.org/10.1016/j.msard.2012.06.002

Kimbrough, DJ, Fujihara, K, Jacob, A, Lana-Peixoto, MA, Isabel Leite, M, Levy, M, Marignier, R, Nakashima, I, Palace, J, De Seze, J, Stuve, O, Tenembaum, SN, Traboulsee, A, Waubant, E, Weinshenker, BG & Wingerchuk, DM 2012, 'Treatment of neuromyelitis optica: Review and recommendations', Multiple Sclerosis and Related Disorders, vol. 1, no. 4, pp. 180-187. https://doi.org/10.1016/j.msard.2012.06.002

@article{8918900471ba49f9a2199a7431a3aa61,

title = "Treatment of neuromyelitis optica: Review and recommendations",

abstract = "Neuromyelitis optica (NMO) is an autoimmune demyelinating disease preferentially targeting the optic nerves and spinal cord. Once regarded as a variant of multiple sclerosis (MS), NMO is now recognized to be a different disease with unique pathology and immunopathogenesis that does not respond to traditional MS immunomodulators such as interferons. Preventive therapy in NMO has focused on a range of immunosuppressive medications, none of which have been validated in a rigorous randomized trial. However, multiple retrospective and a few recent prospective studies have provided evidence for the use of six medications for the prevention of NMO exacerbations: azathioprine, rituximab, mycophenolate mofetil, prednisone, methotrexate and mitoxantrone. This review provides a comprehensive analysis of each of these medications in NMO and concludes with a set of recommended consensus practices.",

keywords = "Aquaporin 4, Immunosuppression, NMO treatment, Neuromyelitis optica, Optic neuritis, Transverse myelitis",

author = "Kimbrough, {Dorlan J.} and Kazuo Fujihara and Anu Jacob and Lana-Peixoto, {Marco A.} and {Isabel Leite}, Maria and Michael Levy and Romain Marignier and Ichiro Nakashima and Jacqueline Palace and {De Seze}, Jrme and Olaf Stuve and Tenembaum, {Silvia N.} and Anthony Traboulsee and Emmanuelle Waubant and Weinshenker, {Brian G.} and Wingerchuk, {Dean M.}",

note = "Funding Information: Dr. St{\"u}ve is a recipient of a Doris Duke Clinical Scientist Development Award. Work related to this study was supported by the Doris Duke Charitable Foundation Grant #: 2009036 . ",

year = "2012",

month = oct,

doi = "10.1016/j.msard.2012.06.002",

language = "English (US)",

volume = "1",

pages = "180--187",

journal = "Multiple Sclerosis and Related Disorders",

issn = "2211-0348",

publisher = "Elsevier",

number = "4",

}

TY - JOUR

T1 - Treatment of neuromyelitis optica

T2 - Review and recommendations

AU - Kimbrough, Dorlan J.

AU - Fujihara, Kazuo

AU - Jacob, Anu

AU - Lana-Peixoto, Marco A.

AU - Isabel Leite, Maria

AU - Levy, Michael

AU - Marignier, Romain

AU - Nakashima, Ichiro

AU - Palace, Jacqueline

AU - De Seze, Jrme

AU - Stuve, Olaf

AU - Tenembaum, Silvia N.

AU - Traboulsee, Anthony

AU - Waubant, Emmanuelle

AU - Weinshenker, Brian G.

AU - Wingerchuk, Dean M.

N1 - Funding Information: Dr. Stüve is a recipient of a Doris Duke Clinical Scientist Development Award. Work related to this study was supported by the Doris Duke Charitable Foundation Grant #: 2009036 .

PY - 2012/10

Y1 - 2012/10

N2 - Neuromyelitis optica (NMO) is an autoimmune demyelinating disease preferentially targeting the optic nerves and spinal cord. Once regarded as a variant of multiple sclerosis (MS), NMO is now recognized to be a different disease with unique pathology and immunopathogenesis that does not respond to traditional MS immunomodulators such as interferons. Preventive therapy in NMO has focused on a range of immunosuppressive medications, none of which have been validated in a rigorous randomized trial. However, multiple retrospective and a few recent prospective studies have provided evidence for the use of six medications for the prevention of NMO exacerbations: azathioprine, rituximab, mycophenolate mofetil, prednisone, methotrexate and mitoxantrone. This review provides a comprehensive analysis of each of these medications in NMO and concludes with a set of recommended consensus practices.

AB - Neuromyelitis optica (NMO) is an autoimmune demyelinating disease preferentially targeting the optic nerves and spinal cord. Once regarded as a variant of multiple sclerosis (MS), NMO is now recognized to be a different disease with unique pathology and immunopathogenesis that does not respond to traditional MS immunomodulators such as interferons. Preventive therapy in NMO has focused on a range of immunosuppressive medications, none of which have been validated in a rigorous randomized trial. However, multiple retrospective and a few recent prospective studies have provided evidence for the use of six medications for the prevention of NMO exacerbations: azathioprine, rituximab, mycophenolate mofetil, prednisone, methotrexate and mitoxantrone. This review provides a comprehensive analysis of each of these medications in NMO and concludes with a set of recommended consensus practices.

KW - Aquaporin 4

KW - Immunosuppression

KW - NMO treatment

KW - Neuromyelitis optica

KW - Optic neuritis

KW - Transverse myelitis

UR - http://www.scopus.com/inward/record.url?scp=84865262140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865262140&partnerID=8YFLogxK

U2 - 10.1016/j.msard.2012.06.002

DO - 10.1016/j.msard.2012.06.002

M3 - Review article

AN - SCOPUS:84865262140

SN - 2211-0348

VL - 1

SP - 180

EP - 187

JO - Multiple Sclerosis and Related Disorders

JF - Multiple Sclerosis and Related Disorders

IS - 4

ER -

Treatment of neuromyelitis optica: Review and recommendations

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this